Collaboration Agreements - Narrative (Details) $ in Thousands |
1 Months Ended | 3 Months Ended | 9 Months Ended | |
|---|---|---|---|---|
Mar. 31, 2024 |
Sep. 30, 2024
USD ($)
right
|
Sep. 30, 2024
USD ($)
right
|
Dec. 31, 2023
USD ($)
|
|
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
| Short-term deferred revenue | $ 14,684 | $ 14,684 | $ 8,221 | |
| Long-term deferred revenue | $ 54,204 | $ 54,204 | $ 60,667 | |
| Bristol Myers Squibb Company ("BMS") | Amended Collaboration Agreement 2019 | ||||
| Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] | ||||
| Agreement extension period, options to extend | 2 years | |||
| Number of material rights | right | 18 | 18 | ||
| Transaction price | $ 56,700 | $ 56,700 | ||
| Short-term deferred revenue | 6,500 | 6,500 | ||
| Long-term deferred revenue | $ 50,200 | $ 50,200 |